ENSPRYNG – (Satralizumab)

Enspryng contains the active substance satralizumab. It is a type of protein called a monoclonal antibody. Monoclonal antibodies are designed to recognize a specific substance in the body and bind to it. is used for the treatment of neuromyelitis optica spectrum disorder (TENMO) in adults and adolescents aged 12 years and over. Enspryng blocks the action of a protein called interleukin 6 (IL-6), which is involved in the process that leads to damage and inflammation in the nervous system. By blocking its effects, Enspryng reduces the risk of TENMO recurring or flare-up.